Mostrar el registro sencillo del ítem
dc.contributor.author | Salmanton-García, Jon | |
dc.contributor.author | Hoenigl, Martin | |
dc.contributor.author | Gangneux, Jean-Pierre | |
dc.contributor.author | Segal, Esther | |
dc.contributor.author | Alastruey-Izquierdo, Ana | |
dc.contributor.author | Arikan Akdagli, Sevtap | |
dc.contributor.author | Lagrou, Katrien | |
dc.contributor.author | Özenci, Volkan | |
dc.contributor.author | Vena, Antonio | |
dc.contributor.author | Cornely, Oliver A | |
dc.date.accessioned | 2023-08-25T07:54:41Z | |
dc.date.available | 2023-08-25T07:54:41Z | |
dc.date.issued | 2023-01 | |
dc.identifier.citation | Lancet Microbe. 2023 Jan;4(1):e47-e56. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16341 | |
dc.description.abstract | Access to the appropriate tools is crucial for early diagnosis and clinical management of invasive fungal infections. This Review aims to describe the invasive fungal infection diagnostic capacity of Europe to better understand the status and the most pressing aspects that need improvement. To our knowledge, this is the first time that the mycological diagnostic capability and access to antifungal treatments of institutions has been evaluated at a pan-European level. Between Nov 1, 2021, and Jan 31, 2022, 388 institutions in Europe self-assessed their invasive fungal infection management capability. Of the 388 participating institutions from 45 countries, 383 (99%) had access to cultures, 375 (97%) to microscopy, 363 (94%) to antigen-detection assays, 329 (85%) to molecular tests (mostly PCR), and 324 (84%) to antibody tests for diagnosis and management. With the exception of microscopy, there were considerable differences in access to techniques among countries according to their gross domestic product. At least one triazole was available in 363 (94%) of the institutions, one echinocandin in 346 (89%), and liposomal amphotericin B in 301 (78%), with country gross domestic product-based differences. Differences were also observed in the access to therapeutic drug monitoring. Although Europe is well prepared to manage invasive fungal infections, some institutions do not have access to certain diagnostic tools and antifungal drugs, despite most being considered essential by WHO. These limitations need to be overcome to ensure that all patients receive the best diagnostic and therapeutic management. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Antifungal Agents | es_ES |
dc.subject.mesh | Invasive Fungal Infections | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Mycology | es_ES |
dc.subject.mesh | Echinocandins | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.title | The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey | es_ES |
dc.type | review article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 36463916 | es_ES |
dc.format.volume | 4 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | e47-e56 | es_ES |
dc.identifier.doi | 10.1016/S2666-5247(22)00261-0 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2666-5247 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/S2666-5247(22)00261-0 | es_ES |
dc.identifier.journal | The Lancet. Microbe | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |